WAS
ICPT

WESPAC Advisors SoCal’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

WESPAC Advisors SoCal’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-100
Closed -$14K – 328
2015
Q4 		$14K Buy
+100
New +$16.9K 0.01% 180

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

WESPAC Advisors SoCal's ICPT Position: Q1 2016 in Review

WESPAC Advisors SoCal sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2016, closing a stake of 100 shares — an estimated $14K sold.

WESPAC Advisors SoCal first reported a position in ICPT in Q4 2015 and held it in 1 quarter. The position peaked at $14K in Q4 2015. 160 funds tracked by Wall St. Rank hold ICPT as of Q1 2016.

  • WESPAC Advisors SoCal reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • WESPAC Advisors SoCal sold 100 Intercept Pharmaceuticals, Inc. shares in Q1 2016, an estimated $14K.
  • WESPAC Advisors SoCal first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • WESPAC Advisors SoCal's Intercept Pharmaceuticals, Inc. position peaked at $14K in Q4 2015.
  • 160 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2016.

Based on WESPAC Advisors SoCal's 13F filing for Q1 2016, filed 12 Aug 2016.